Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

689
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
689
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

231
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
231
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

8.6K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.6K
tRNA Activation02:26

tRNA Activation

22.9K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
22.9K
Activation Energy01:26

Activation Energy

86.6K
Activation energy is the minimum amount of energy necessary for a chemical reaction to move forward. The higher the activation energy, the slower the rate of the reaction. However, adding heat to the reaction will increase the rate, since it causes molecules to move faster and increase the likelihood that molecules will collide. The collision and breaking of bonds represents the uphill phase of a reaction and generates the transition state. The transition state is an unstable high-energy state...
86.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Feb 2, 2026

GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization
11:38

GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization

Published on: October 24, 2011

15.9K

Two-Drug Cocktail Active against RCC

    Cancer Discovery
    |November 11, 2018
    PubMed
    Summary

    Avelumab plus axitinib significantly improved progression-free survival by 64% compared to sunitinib in advanced renal cell carcinoma patients. This combination therapy also doubled response rates with comparable safety profiles.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Medical Oncology

    Background:

    • Advanced renal cell carcinoma (RCC) presents a significant clinical challenge.
    • Sunitinib has been a standard first-line treatment for advanced RCC.
    • Novel combination therapies are needed to improve patient outcomes.

    Discussion:

    • The combination of avelumab (an immune checkpoint inhibitor) and axitinib (a tyrosine kinase inhibitor) demonstrated superior efficacy in advanced RCC.
    • This combination therapy resulted in a 64% increase in progression-free survival (PFS) compared to sunitinib.
    • Objective response rates were significantly higher with avelumab plus axitinib (51%) versus sunitinib (26%).

    Key Insights:

    • Avelumab plus axitinib represents a new standard of care for first-line advanced RCC.

    More Related Videos

    A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood
    08:17

    A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood

    Published on: February 8, 2016

    11.2K
    Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
    10:22

    Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

    Published on: September 16, 2011

    34.1K

    Related Experiment Videos

    Last Updated: Feb 2, 2026

    GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization
    11:38

    GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization

    Published on: October 24, 2011

    15.9K
    A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood
    08:17

    A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood

    Published on: February 8, 2016

    11.2K
    Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
    10:22

    Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

    Published on: September 16, 2011

    34.1K
  • The combination therapy offers a substantial improvement in PFS and response rates.
  • The safety profile of avelumab plus axitinib was comparable to sunitinib, with similar rates of grade 3 or 4 side effects.

    • Outlook:

    • Further research may explore long-term survival benefits and patient-reported outcomes.
    • This combination could potentially be investigated in earlier stages of renal cell carcinoma.
    • The findings support the role of combining immunotherapy with targeted therapy in RCC treatment.